Tofacitinib is a JAK1/3 inhibitor, with less efficacy vs. JAK2 and TYK2, and it is approved for the treatment of rheumatoid arthritis, psoriatic arthritis and ulcerative colitis (164). This evidence concerns the gene JAK1 and rheumatoid arthritis.